NCT07732114

Brief Summary

This prospective observational diagnostic accuracy study investigates the efficacy of the hepatic vein systolic filling fraction (SFF) as a real-time, non-invasive indicator of right ventricular (RV) systolic function in critically ill patients admitted to the intensive care unit.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
115

participants targeted

Target at P50-P75 for all trials

Timeline
12mo left

Started Jul 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress8%
Jul 2026Jul 2027

Study Start

First participant enrolled

July 1, 2026

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

July 18, 2026

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 28, 2026

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2027

Expected
14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2027

Last Updated

July 28, 2026

Status Verified

July 1, 2026

Enrollment Period

1 year

First QC Date

July 18, 2026

Last Update Submit

July 27, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Hepatic vein systolic filling fraction (SFF) and Tricuspid Annular Plane Systolic Excursion (TAPSE)

    Hepatic vein systolic filling fraction (SFF) will be measured using colour Doppler ultrasonography of the hepatic vein. Examinations will be performed within a 5-minute window of transthoracic echocardiography and obtained at end-expiration to minimise the effects of respiratory variation. All patients will be mechanically ventilated, and positive end-expiratory pressure (PEEP) and plateau pressure will be recorded at the time of assessment. Unit: Percentage (%) Right ventricular systolic function will be assessed by measuring tricuspid annular plane systolic excursion (TAPSE) using transthoracic echocardiography at the bedside. Echocardiographic examination will be performed within a 5-minute window of hepatic vein Doppler assessment and obtained at end-expiration to minimise respiratory variation. All patients will be mechanically ventilated, and positive end-expiratory pressure (PEEP) and plateau pressure will be recorded at the time of assessment. Unit: Millimetres mm

    within the first 24 hours

Secondary Outcomes (1)

  • Baseline Demographic and Clinical Data, Synchronized Hemodynamic and Respiratory Data, Total length of ICU stay (days) and ICU mortality and the correlation and agreement between the hepatic vein and RV systolic function via TAPSE.

    till 28 days after admission

Interventions

1\. Point-of-Care Echocardiography Protocol Echocardiograms were recorded within the first 24 hours of ICU admission using an echocardiograph by two intensivists who were experienced in echocardiography (more than 7 years of experience) and will be blinded to the study. Electrocardiograms were recorded continuously during the echocardiographic examination. Images will be saved for offline analysis. The ultrasound machine will be equipped with a phased-array transducer. Right Ventricular Assessment: From the apical 4-chamber view, the M-mode cursor will be aligned with the lateral aspect of the tricuspid valve annulus to measure the Tricuspid Annular Plane Systolic Excursion (TAPSE). To ensure accuracy and account for beat-to-beat variability, the final TAPSE value recorded for each patient will be the average of measurements taken over three consecutive cardiac cycles. Right ventricular systolic dysfunction (RVSD) is strictly defined as an average TAPSE of \< 16 mm (7).

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

1. Age ≥ 18 years. 2. Mechanically ventilated patients 3. Patients in whom transthoracic echocardiography (TTE) can be performed Adequate acoustic window to measure TAPSE. 4. Patients in whom hepatic vein Doppler assessment is feasible Adequate subcostal view for Doppler sampling.

You may qualify if:

  • Age ≥ 18 years.
  • Mechanically ventilated patients
  • Patients in whom transthoracic echocardiography (TTE) can be performed Adequate acoustic window to measure TAPSE.
  • Patients in whom hepatic vein Doppler assessment is feasible Adequate subcostal view for Doppler sampling.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Menoufia University

Alexandria, Shebin El-Kom, 32511, Egypt

RECRUITING

Central Study Contacts

Nevine Mostafa Soliman, Ass. Prof.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ass. Prof.

Study Record Dates

First Submitted

July 18, 2026

First Posted

July 28, 2026

Study Start

July 1, 2026

Primary Completion (Estimated)

July 1, 2027

Study Completion (Estimated)

July 15, 2027

Last Updated

July 28, 2026

Record last verified: 2026-07

Locations